Prometheus Biosciences Inc, a biopharmaceutical company involved in the discovery, development, and commercialisation of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced yesterday that it has named Thierry Dervieux, PharmD, PhD, DABCC as its new chief development officer, diagnostics, and medical laboratory director.
Dr Dervieux joins Prometheus Biosciences from Exagen Diagnostics where he served as chief scientific officer and medical director. Prior to joining Exagen, Dr Dervieux was vice president of research and development at Cypress Bioscience Inc and senior director of research and development with Proprius Pharmaceuticals Inc. Prior to that, he served as principal scientist and director of research and development at Prometheus Laboratories.
Mark McKenna, chief executive officer of Prometheus Biosciences, said, 'Thierry's deep expertise in the development of innovative diagnostic assays and drug monitoring tools will benefit us greatly as we continue to advance our novel precision medicine platform for GI and autoimmune conditions. We are thrilled to welcome Thierry and we look forward to his contributions as we take Prometheus to the next level.'
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
TuHURA Biosciences acquires Kineta
AbbVie agrees to acquire Capstan Therapeutics
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer